Taro Pharmaceutical Industries Stock Price To Earning
| TARODelisted Stock | USD 42.97 0.00 0.00% |
Taro Pharmaceutical Industries fundamentals help investors to digest information that contributes to Taro Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Taro Stock. The fundamental analysis module provides a way to measure Taro Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taro Pharmaceutical stock.
Taro |
Taro Pharmaceutical Industries Company Price To Earning Analysis
Taro Pharmaceutical's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Taro Pharmaceutical Price To Earning | 14.57 X |
Most of Taro Pharmaceutical's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taro Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Taro Pharmaceutical Industries has a Price To Earning of 14.57 times. This is 43.61% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earning for all United States stocks is 49.27% higher than that of the company.
Taro Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taro Pharmaceutical's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taro Pharmaceutical could also be used in its relative valuation, which is a method of valuing Taro Pharmaceutical by comparing valuation metrics of similar companies.Taro Pharmaceutical is currently under evaluation in price to earning category among its peers.
Taro Fundamentals
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 735.67 M | |||
| Shares Outstanding | 37.58 M | |||
| Shares Owned By Insiders | 78.48 % | |||
| Shares Owned By Institutions | 13.06 % | |||
| Number Of Shares Shorted | 73.56 K | |||
| Price To Earning | 14.57 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 2.59 X | |||
| Revenue | 629.18 M | |||
| Gross Profit | 293.13 M | |||
| EBITDA | 52.6 M | |||
| Net Income | 53.87 M | |||
| Cash And Equivalents | 806.25 M | |||
| Cash Per Share | 21.45 X | |||
| Total Debt | 369.06 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 3.60 X | |||
| Book Value Per Share | 47.70 X | |||
| Cash Flow From Operations | 132.39 M | |||
| Short Ratio | 3.20 X | |||
| Earnings Per Share | 1.43 X | |||
| Target Price | 43.0 | |||
| Number Of Employees | 24 | |||
| Beta | 0.56 | |||
| Market Capitalization | 1.62 B | |||
| Total Asset | 2.16 B | |||
| Retained Earnings | 2.41 B | |||
| Working Capital | 950.88 M | |||
| Current Asset | 1.88 B | |||
| Current Liabilities | 245.46 M | |||
| Net Asset | 2.16 B |
About Taro Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taro Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taro Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taro Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Taro Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taro Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taro Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Taro Stock
| 0.9 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.87 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.85 | HYMTF | Hyundai Motor | PairCorr |
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.78 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Taro Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taro Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taro Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taro Pharmaceutical Industries to buy it.
The correlation of Taro Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taro Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taro Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taro Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Taro Stock
If you are still planning to invest in Taro Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taro Pharmaceutical's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |